Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, will conduct …
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) this week announced the completion of enrollment into ATI-1777-AD-202, its Phase 2b trial of its investigational topical “soft” Janus kinase (JAK) 1/3 …
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202) Read More
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) announced the recent completion of the initial analysis of OLINVYK continuous respiratory monitoring data from the VOLITION study.
Trevena’s Exciting Findings: Insights on OLINVYK’s Impact on Respiratory Health to be Revealed at ASA Conference Read More
BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced the recent results of two pre-clinical Probudur™ dose escalation studies.
Virpax Pharmaceuticals Announces Results of Probudur Dose Escalation Studies Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) recenlty announced positive results from ATI-2138-PKPD-102, a Phase 1 Multiple Ascending Dose (MAD) trial of the investigational compound ATI-2138.
Aclaris Therapeutics Unveils Promising Phase 1 Study of ATI-2138 Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company, announced a clinical study update for Retinitis Pigmentosa (RP) participants treated in the Phase 1/2 trial to assess the safety …
Promising Update: Ocugen’s Gene Therapy for Retinitis Pigmentosa Shows Positive Results in Phase 1/2 Trial Read More
BERWYN, PA — Panavance Therapeutics Inc. announced the recent publication of positive data in the peer-reviewed Journal of Cellular and Molecular Medicine in a manuscript titled, “GP-2250, a novel anticancer agent, …
Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, recently announced preliminary topline data from two Phase 1 proof-of-concept studies of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for …
Trevena’s TRV045: Promising Results in Neuropathic Pain Trials with CNS Target Engagement Read More
WAYNE, PA — XyloCor Therapeutics, Inc., a clinical‑stage biopharmaceutical company, recenlty presented results from the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) of its lead gene therapy …
XyloCor Therapeutics Unveils Exciting Phase 2 Results of XC001 at ESC Congress 2023! Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company, this week announced the presentation of lesion clearance data from Part 1 of an ongoing Phase 2 …
Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 Read More